Hologic, Inc. revised earnings guidance for the Fiscal year 2024. For the year, the Company expects revenues of $4,000 million to $4,050 million compared to previous guidance of $3,990 million to $4,065 million and GAAP EPS of $3.45 to $3.55 compared to previous guidance of $3.52 to $3.67.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
73.96 USD | -0.04% | -1.36% | +3.57% |
May. 22 | FDA classifies recall of Hologic's implant as 'most serious' | RE |
May. 22 | FDA classifies recall of Hologic's implants for soft tissue as 'most serious' | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.57% | 17.27B | |
+9.68% | 223B | |
+13.20% | 194B | |
+20.17% | 141B | |
+30.84% | 109B | |
+2.05% | 64.85B | |
+15.45% | 52.7B | |
+3.96% | 51.77B | |
+7.69% | 44.12B | |
+3.61% | 36.21B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024